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Poster Session I S281and craniofacial development. Busulfan (Bu) is an alkylating agent
that can be combined with cyclophosphamide (Cy) in order to
avoid use of TBI in children. The hypothesis to be tested in this
study was that children conditioned with Bu/Cy have fewer distur-
bances in dental development compared to those conditioned with
TBI/Cy.
Patients andMethods:The present study included 81 recipients of
allogeneic HSCT and grafted between January 1980 and 2001. 57
children were treated with TBI and 24 with Bu/Cy. Panoramic ra-
diographs were examined for aplasia, microdontia (reduction in
crown size) and disturbances in root development of permanent
teeth.
Results: When excluding third molars 19% (11/57) in the TBI/
CY-group and 19% (5/28) in the BU/CY-group exhibited one or
more missing teeth (p 5 0.7863). In both groups there were a sta-
tistically significant negative correlation between age at HSCT and
the number of missing teeth (p\0.001). In the TBI/Cy group 23%
(13/57) compared to 52% (12/23) in the Bu/Cy group exhibited
microdontia (p 5 0.0119). Seventy-three percent (41/56) in the
TBI/CY-group compared to 87% (20/23) in the BU/CY-group ex-
hibited disturbances in root development. The mean number of
teeth exhibiting disturbances in root development was 12.2 6 9.6
in the TBI/CY-group and 10.3 6 8.6 in the BU/CY-group
(p 5 0.5726).
Conclusion: The results show that busulfan is as toxic as TBI with
regard to causing disturbances in dental development. Long-term
survivors need careful dental follow-up to facilitate early diagnosis
and planning of dental treatment.210
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Background: The onset of cutaneous complications following he-
matopoietic stem cell transplantation (HSCT) has an impact on the
well-being of post-transplant patients. These sequelae include ad-
verse drug reactions, toxic erythema of chemotherapy, viral exan-
thema, eruption of lymphocyte recovery and graft-versus-host
disease (GVHD). Such skin toxicities can have a profound effect
on quality of life (QoL). Using a dermatology-specific question-
naire, we investigated the impact of dermatologic events after
HSCT.
Methods: Patients completed the Skindex-16, a questionnaire
that measures the effects of skin disease on patient QoL with re-
spect to symptoms, emotions, and functional status, based on
a 0-6 scale from least to most severe. Correlation of Skindex-
16 scores was made to patient gender, age, ethnicity, underlying
disease, type of HSCT, conditioning regimen, post-HSCT im-
munosuppressive medications, and presence/severity of acute
and chronic GVHD according to Glucksberg criteria and
the 2005 National Institute of Health Consensus Conference
respectively.
Results:There was a statistically significant increase in mean scores
for patient emotions (49.7) related to skin toxicities followingHSCT
as compared to both symptom scores (34.5, p5 .044) and functional
status scores (19.8, p\.001). There were no significant differences
between QoL scores associated with patient gender, age, ethnicity,
underlying disease, type of HSCT, conditioning regimen, post-
HSCT immunosuppressive medications, and presence/severity of
acute and chronic GVHD.
Conclusions: GVHD and other cutaneous sequelae of HSCT
adversely impacted patient QoL with respect to emotional state
as compared to symptoms or functional derangements related to
skin eruptions post-HSCT. These results suggest that patient
counseling is an essential component of medical care for pa-
tients with GVHD and other skin toxicities that result from
transplantation.211
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HCT recipients are at high risk for psychological distress, partic-
ularly depression and anxiety, with reported prevalence rates as
high as 40%, but there is a paucity of research evaluating how med-
ical treatment-related variables might contribute to these symp-
toms. Our study investigated the feasibility of a brief
psychological screening in routine outpatient care of 101 adult-
HCT survivors. Participants completed the diagnostically-focused
Patient Health Questionnaire (PHQ), assessing for depressive dis-
orders, anxiety, and substance abuse. Median time to study partic-
ipation was 276 days post-HCT (range 20-1821 days). Of the entire
cohort (18 autologous, 83 allogeneic HCT), 22% endorsed the 9-
item depressive symptoms subscale (PHQ9; range 0-27) in the clin-
ically significant range of at least moderate depression (score $ 10);
19.8% scored in the mild range (score 5-9). As mean PHQ9 scores
of autologous and allogeneic HCT did not differ significantly, we
limited further analysis to allogeneic HCT recipients only. Linear
multiple regression analysis with forced entry yielded a model ac-
counting for 22.5% of the variance in depressive symptoms
(F (8,74) 5 3.98; p\ .001).
Table. Linear Multiple Regression Model with Forced Entry
Predicting Depressive Symptoms in Allogeneic Transplant
Patients, Controlling for Relapse, Steroid Dose at Time of
Study, and Age at HCT
PREDICTORS BETA p VALUEFull Intensity* 0.32 0.004
Steroids for aGVHD prior to study** 0.42 0.001
Unrelated donor HCT*** -0.34 0.002
Any GVHD prior to study**** -0.32 0.009
Days from HCT prior to study 0.27 0.014
Relapse prior to study 0.03 0.743
Steroid dose (mg/kg) at study entry 0.17 0.100
Age at HCT 0.15 0.175*Full vs reduced intensity conditioning regimen; thus full intensity had
more depression
**Steroids for acute GVHD; thus treated with steroids were more
depressed
***Unrelated vs related; thus related had more depression
****Any GVHD (acute or chronic) before study; thus those without
GVHD had more depression
More depressive symptoms were significantly associated with full
intensity conditioning regimen, steroid treatment for acute
GVHD, and more days since transplant. Less depression was asso-
ciated with unrelated HCT compared to related HCT, and any
form of GVHD compared to none. Thus, long-term HCT survi-
vors were more likely to be depressed, and patients with GVHD
were less depressed. However, patients with acute GVHD treated
with steroids were more likely to be depressed. One explanation
may be that unrelated graft recipients and those experiencing
GVHD had lower expectations of good outcome, or greater social
support. To explore how heavily the medical predictors loaded on
somatic symptoms associated with depression, we assessed the 5
PHQ cognitive/affective items (i.e., omitting the 4 somatic items)
onto the same set of predictor variables, producing a statistically
significant model accounting for 19.4% of the variance (p\ .01),
suggesting that medical variables contributed significantly to the
variance in cognitive and affective depressive symptoms alone.
These data for this hypothesis-generating pilot are now being
used to design a future prospective study mapping the trajectory
of depression from pre-HCT through various time points post-
HCT in relation to biomedical variables.
